This study evaluated the effects of tofogliflozin, an SGLT2 inhibitor that has been clinically used in Japan, on the brachial-ankle pulse wave velocity (baPWV) as one of the prespecified secondary outcomes of the using tofogliflozin for possible better intervention against atherosclerosis for type 2 diabetes patients (UTOPIA) trial [22, 23]. Here, SLC5A2 is linked to type 2 diabetes mellitus.